8 completed, 4 recruiting, 2 active not recruiting, 2 unknown. 16 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 8, Recruiting 4, Active not recruiting 2, Unknown 2 |
| Phase 2 | 4 | Recruiting 2, Completed 1, Unknown 1 |
Follow Granuloma: new trials by email Literature Review of Granuloma trials Research Report on Granuloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The GranStone Trial empagliflozin (Jardiance) 25 mg, Losartan 100 mg - Paraffinoma, Granuloma, Foreign-Body | Phase 2 / Phase 3 | Recruiting | Martin Blomberg Jensen | 100 | 2026-10-20 | 2026-11-10 |
| Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-07-24 | 2026-11-13 |
| A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases Benralizumab - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES) | Phase 3 | Recruiting | AstraZeneca | 14 | 2025-04-17 | 2026-10-28 |
| A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） SHR-1703, Mepolizumab Injection - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 166 | 2023-11-16 | 2025-12-04 |
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo - Pulmonary Sarcoidosis | Phase 3 | Completed | aTyr Pharma, Inc. | 268 | 2022-09-15 | 2026-06-04 |
| Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Depemokimab, Mepolizumab, Placebo matching mepolizumab - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Active not recruiting | GlaxoSmithKline | 163 | 2022-07-14 | 2026-07-08 |
| Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Mepolizumab, cyclophosphamide/azathioprine, Placebo - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 102 | 2022-05-30 | 2026-10-01 |
| Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. Benralizumab, Mepolizumab, Placebo to Mepolizumab - Eosinophilic Granulomatous Vasculitis | Phase 3 | Active not recruiting | AstraZeneca | 140 | 2019-10-29 | 2026-11-09 |
| Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors Crizotinib - Inflammatory Myofibroblastic Tumor | Phase 2 / Phase 3 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 25 | 2019-02-01 | 2019-03-14 |
| Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Rituximab, Azathioprine, Placebo-rituximab - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 98 | 2018-03-07 | 2025-11-20 |
| Rituximab in Eosinophilic Granulomatosis With Polyangiitis Rituximab, Placebo-rituximab, Cyclophosphamide - Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 107 | 2016-12-05 | 2026-01-15 |
| Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Mepolizumab, Prednisolone - Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | GlaxoSmithKline | 100 | 2015-04-14 | 2024-03-12 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Mepolizumab, Placebo - Churg-Strauss Syndrome | Phase 3 | Completed | GlaxoSmithKline | 136 | 2014-02-05 | 2018-01-31 |
| Simple Hygiene Versus Alcohol Based Usual Care for Umbilical Cord Hygiene, Usual alcohol care - Infection, Skin Diseases, Bacterial | Phase 3 | Unknown | ASST Fatebenefratelli Sacco | 400 | 2011-05-01 | 2011-06-08 |
| Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) corticosteroid and azathioprine, corticosteroid and placebo - MPA, PAN or EGPA With FFS=0 | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 114 | 2008-05-01 | 2025-09-12 |
Churg-Strauss Syndrome (11) · Granuloma, Plasma Cell (2) · Asthma (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Chondrosarcoma, Mesenchymal (1) · Dermatofibrosarcoma (1) · Fibrosarcoma (1) · Fibrosis (1) · Granuloma, Foreign-Body (1) · Histiocytoma, Angiomatoid Fibrous (1) · Histiocytoma, Malignant Fibrous (1) · Hypercalcemia (1) · Hypereosinophilic Syndrome (1) · Infections (1)
Hemic and Lymphatic Diseases (13) · Lymphatic Diseases (13) · Immune System Diseases (12) · Lymphoproliferative Disorders (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (11) · Autoimmune Diseases (11) · Cardiovascular Diseases (11) · Skin Diseases, Vascular (11) · Vascular Diseases (11) · Systemic Vasculitis (10) · Vasculitis (10) · Pathologic Processes (5)
mepolizumab (6) · Azathioprine (3) · benralizumab (3) · Cyclophosphamide (2) · Rituximab (2) · Adrenal Cortex Hormones (1) · Crizotinib (1) · Doxorubicin (1) · Ethanol (1) · Hygiene (1) · Ifosfamide (1) · Losartan (1) · Prednisolone (1) · Radiation (1) · Radiotherapy (1)
Assistance Publique - Hôpitaux de Paris (4) · AstraZeneca (3) · GlaxoSmithKline (3) · ASST Fatebenefratelli Sacco (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Martin Blomberg Jensen (1) · National Cancer Institute (NCI) (1) · aTyr Pharma, Inc. (1)
France (11) · United States (8) · Canada (7) · Italy (6) · United Kingdom (6) · Germany (5) · Japan (5) · Belgium (4) · Israel (4) · Netherlands (4) · Brazil (3) · Poland (3) · Spain (3) · Argentina (2) · Austria (2)
Aaron R Weiss (1) · Benjamin Terrier (1) · Cristina Meroni (1) · Lisa Carey (1) · Loic Guillevin, MD, PhD (1) · Ludovica Tagliabue, MD (1) · Maria Teresa Garavaglia (1) · Martin B Jensen, Professor (1) · Michael Wechsler, MD (1)
PMID 28514601, PMID 28678392, PMID 31056661, PMID 32702309, PMID 32827353, PMID 33164993, PMID 34515544, PMID 37523624, PMID 37902990, PMID 38393328, PMID 40008472, PMID 40720835, PMID 40977418
2023 (3), 2016 (2), 2014 (1), 2019 (1), U10CA098543 (1), U10CA180830 (1), U10CA180886 (1)